And how long before a Phase III trial?
http://www.benzinga.com/news/13/10/3988205/acorda-therapeutics-reports-data-from-phase-2-trial-of-delfampridine-er-says-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29
Acorda Therapeutics, Inc. (Nasdaq: ACOR [FREE Stock Trend Analysis]) today announced data from a Phase 2
proof-of-concept study of dalfampridine extended release tablets, 10 mg
(dalfampridine-ER) in people with post-stroke deficits. In the study,
treatment with dalfampridine-ER was well-tolerated and improved walking, as
measured by the Timed 25-Foot Walk test (T25FW). The data were presented at
the American Neurological Association 2013 Annual Meeting, being held in New
Orleans. Top-line data from this study were disclosed by the Company in April
2013.
No comments:
Post a Comment